October 2026

Six peptides, including BPC-157, can now be compounded by 503A pharmacies, but only if every strict condition is met. HHS's new policy is temporary, it isn't FDA approval, and it doesn't cover 503B outsourcing facilities. Here's what changed, what didn't, and six questions to ask any pharmacy before you order.

The Food and Drug Administration (FDA) has drafted a temporary policy that may allow pharmacies to compound certain peptides. It’s under White House review. Nobody outside government has seen it, and nothing has changed yet. Whether you’re a patient, a nurse or a physician, here’s what’s known and what isn’t.

On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee recommended six peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide (DSIP). The recommendation is advice to FDA, not a final decision, so these peptides still can't be legally compounded, and the vote doesn't apply to 503B outsourcing facilities. Here's what the vote means for your practice and what FDA has to do next.

Learn where BPC-157 and other peptides currently stand in the FDA's regulatory process. Explore the differences between 503A pharmacies and 503B outsourcing facilities, recent FDA developments, and what these changes could mean for medical practices. Stay informed on compounding requirements and important considerations when evaluating peptide suppliers.